CDK4 and cancer: Development of clinically successful CDK4/6 inhibitors (CDK4/6i) like Palbociclib (PD 0332991), which can cause G1-phase arrest by targeting the Cyclin D-CDK4/6 complexes, has been a significant breakthrough in cancer treatment [60].